by: Parent Project Muscular Dystrophy
Bone health is an important aspect of living with Duchenne muscular dystrophy. Roche recently joined PPMD for a webinar during which Maitea Guridi, a Principal Clinical Scientist at Roche, shared learnings around the natural history of bone health in Duchenne.
We discussed why fractures occur, with Maitea explaining that communication between muscles and bone is disrupted in Duchenne, resulting in weakened bones that are more susceptible to fracture. Roche detailed how the SHIELD study will explore the potential of satralizumab to target both bone health and muscle function in Duchenne, and answered questions from the audience about the study and participation.
